Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Chemoradiotherapy（CRT） is the main treatment for esophageal cancer patients with recurrent
desease，and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal
cancer. Therefore, PD-1 combined with chemoradiotherapy （CRT）may further improve the efficacy
and become a new method for the treatment of esophageal cancer.This study intends to conduct
a single-arm, prospective clinical study, aiming to evaluate the safety and efficacy of PD-1
combined with chemoradiotherapy(CRT) in patients with oligometastatic esophageal squamous
cell carcinoma.